These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

839 related items for PubMed ID: 15709163

  • 1. Pemetrexed in malignant pleural mesothelioma.
    Hazarika M, White RM, Booth BP, Wang YC, Ham DY, Liang CY, Rahman A, Gobburu JV, Li N, Sridhara R, Morse DE, Lostritto R, Garvey P, Johnson JR, Pazdur R.
    Clin Cancer Res; 2005 Feb 01; 11(3):982-92. PubMed ID: 15709163
    [Abstract] [Full Text] [Related]

  • 2. FDA drug approval summaries: pemetrexed (Alimta).
    Hazarika M, White RM, Johnson JR, Pazdur R.
    Oncologist; 2004 Feb 01; 9(5):482-8. PubMed ID: 15477632
    [Abstract] [Full Text] [Related]

  • 3. Pemetrexed: a multitargeted antifolate.
    Rollins KD, Lindley C.
    Clin Ther; 2005 Sep 01; 27(9):1343-82. PubMed ID: 16291410
    [Abstract] [Full Text] [Related]

  • 4. Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.
    Budde LS, Hanna NH.
    Expert Rev Anticancer Ther; 2004 Jun 01; 4(3):361-8. PubMed ID: 15161435
    [Abstract] [Full Text] [Related]

  • 5. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
    Prescrire Int; 2005 Dec 01; 14(80):212-4. PubMed ID: 16400741
    [Abstract] [Full Text] [Related]

  • 6. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
    Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Monberg MJ, Jänne PA, Pemetrexed Expanded Access Program Investigators.
    Lung Cancer; 2007 Feb 01; 55(2):187-94. PubMed ID: 17092602
    [Abstract] [Full Text] [Related]

  • 7. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
    Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, Burris H, Gatzemeier U, Blatter J, Symanowski JT, Rusthoven JJ.
    J Clin Oncol; 2003 Apr 15; 21(8):1556-61. PubMed ID: 12697881
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
    Nakagawa K, Yamazaki K, Kunitoh H, Hida T, Gemba K, Shinkai T, Ichinose Y, Adachi S, Nambu Y, Saijo N, Fukuoka M.
    Jpn J Clin Oncol; 2008 May 15; 38(5):339-46. PubMed ID: 18434338
    [Abstract] [Full Text] [Related]

  • 9. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ, Fink TH, Latz JE, Hossain AM, Musib LC, Thomas M.
    Clin Cancer Res; 2009 Jan 01; 15(1):382-9. PubMed ID: 19118069
    [Abstract] [Full Text] [Related]

  • 10. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
    Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C.
    J Clin Oncol; 2008 Apr 01; 26(10):1698-704. PubMed ID: 18375898
    [Abstract] [Full Text] [Related]

  • 11. Pemetrexed-cisplatin combination in mesothelioma.
    Reck M, Gatzemeier U.
    Expert Rev Anticancer Ther; 2005 Apr 01; 5(2):231-7. PubMed ID: 15877521
    [Abstract] [Full Text] [Related]

  • 12. Pemetrexed therapy for malignant pleural mesothelioma.
    Puto K, Garey JS.
    Ann Pharmacother; 2005 Apr 01; 39(4):678-83. PubMed ID: 15755794
    [Abstract] [Full Text] [Related]

  • 13. The role of Alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials.
    Hanauske AR.
    Lung Cancer; 2004 Aug 01; 45 Suppl 1():S121-4. PubMed ID: 15261444
    [Abstract] [Full Text] [Related]

  • 14. [Update of pemetrexed in thoracic oncology].
    Brechot JM, Morère JF.
    Bull Cancer; 2007 Aug 01; 94 Spec No Actualites():S139-41. PubMed ID: 17845984
    [Abstract] [Full Text] [Related]

  • 15. Second-line treatment for malignant pleural mesothelioma.
    Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A.
    Cancer Treat Rev; 2010 Feb 01; 36(1):24-32. PubMed ID: 19879055
    [Abstract] [Full Text] [Related]

  • 16. [First-line treatment with pemetrexed in association with cisplatin in patients with non-operable malignant pleural mesothelioma].
    Burgin M, Gairard-Dory A-, Mennecier B, Molard A, Beretz L, Quoix A-.
    Rev Pneumol Clin; 2009 Apr 01; 65(2):75-83. PubMed ID: 19375046
    [Abstract] [Full Text] [Related]

  • 17. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
    Kane RC, Farrell AT, Sridhara R, Pazdur R.
    Clin Cancer Res; 2006 May 15; 12(10):2955-60. PubMed ID: 16707588
    [Abstract] [Full Text] [Related]

  • 18. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
    Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ, Santoro A.
    J Clin Oncol; 2006 Mar 20; 24(9):1443-8. PubMed ID: 16549838
    [Abstract] [Full Text] [Related]

  • 19. [Pemetrexed].
    Sudoh J, Gemma A.
    Gan To Kagaku Ryoho; 2008 Jun 20; 35(6):1033-8. PubMed ID: 18633241
    [Abstract] [Full Text] [Related]

  • 20. [Expanded access program in the United States and Alimta program for malignant mesothelioma patients].
    Nambu Y.
    Gan To Kagaku Ryoho; 2007 Feb 20; 34(2):284-6. PubMed ID: 17301544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.